Local News

• Dick Bond leaving Tyson Foods  Dick Bond, president and chief executive officer of Tyson Foods, announced he is leaving the company, effective immediately. Leland Tollett, former chairman and CEO of the company, has agreed to return to the company as President and CEO on an interim basis.
  Tyson Foods, Inc. January 05, 2009  
• PPD enters into strategic collaboration with Merck  PPD announced it has entered into a strategic collaboration with Merck & Co. involving vaccine testing and assay development. Under the agreements, PPD purchased Merck's 130,000 square-foot vaccine testing laboratory and related equipment in Wayne, Penn.
  PPD, Inc. January 05, 2009  
• Cubist Pharmaceuticals, the developer of CUBICIN, announces submission of 2 INDs  Cubist Pharmaceuticals announced that the company submitted two Investigational New Drug Applications (INDs) with the U.S. Food and Drug Administration (FDA) on December 23rd.
  Cubist Pharmaceuticals, Inc. January 05, 2009  
• Bruker Daltonics and Queensland Institute of Medical Research expand collaboration  Bruker Daltonics and the Queensland Institute of Medical Research (QIMR) announced the installation of the first maXis(TM) Ultra-High Resolution Time-Of-Flight (UHR-TOF) mass spectrometer in Australasia, thereby further strengthening the collaboration between Bruker and QIMR.
  Bruker Corporation January 05, 2009  
• Idera announces publication of studies on chemistry of novel antagonists for TLR 7 & 9  Idera Pharmaceuticals announced the publication of studies on the chemistry of novel compounds that have been shown to act as antagonists for Toll-like Receptors (TLR) 7 and 9.
  Idera Pharmaceuticals, Inc. January 05, 2009  
• Alexion Pharmaceuticals and PDL BioPharma resolve patent dispute  PDL BioPharma and Alexion Pharmaceuticals jointly announced that the companies have entered into a definitive license agreement and settlement agreement that resolve the legal disputes between them relating to Alexion's humanized antibody, Soliris(R) (eculizumab) and PDL's patents.
  Alexion Pharmaceuticals, Inc. January 05, 2009  
• Massachusetts may gain biotech plants  Two unidentified life sciences companies are considering developing large biotechnology manufacturing plants in Massachusetts, meaning the Bay State could be poised to become a more significant biotech drug manufacturing center, according to economic development officials.
  The Boston Globe January 03, 2009  Todd Wallack
• FDA blocks Biopure trial  Biopure Corp., a Cambridge biotech company that has struggling to stay afloat while it seeks federal approval for its novel blood substitute, got another dose of bad news.
  The Boston Globe December 31, 2008  
• FDA Cardio Renal Advisory Committee to review Daiichi Sankyo, Lilly drug prasugrel  Daiichi Sankyo Company and Eli Lilly and Company confirmed that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) will review prasugrel during an advisory committee hearing on February 3, 2009.
  Eli Lilly and Company December 31, 2008  
• MLSC to start taking tax break, funding apps on New Year’s Day  The Massachusetts Life Sciences Center, which has been tasked with handling the state's $1 billion Life Sciences Initiative, reports it will start taking online applications for the Life Sciences Tax Incentive Program and the Center's new Life Sciences Accelerator investment program on Jan. 1.
  Mass High Tech December 30, 2008  

   (next 10 articles)